Glioblastoma multiforme (GBM) is a WHO grade IV glioma and the most common malignant,
primary brain tumor with a 5-year survival of 7.2%. Its highly infiltrative nature, genetic …

Glioblastoma is the commonest primary brain tumor, as well as the deadliest. Malignant
gliomas such as glioblastoma multiforme (GBM) present some of the greatest challenges in …

Purpose The clinical significance of epidermal growth factor receptor variant III (EGFRvIII)
expression in glioblastoma multiforme (GBM) and its relationship with other key molecular …

Prognosis for patients suffering from malignant glioma has not substantially improved.
Specific immunotherapy as a novel treatment concept critically depends on target antigens …

Significant work in animal models combined with compelling studies in human patients
together have begun to provide a higher resolution picture of how the immune system …

Conventional therapies for malignant gliomas (MGs) fail to target tumor cells exclusively,
such that their efficacy is ultimately limited by non-specific toxicity. Immunologic targeting of …

The development of effective immunotherapy strategies for glioma requires adequate
understanding of the unique immunological microenvironment in the central nervous system …

Given the highly infiltrative growth pattern of malignant glioma and the lack of specificity
associated with currently available treatment regimens, alternative strategies designed to …

In this study, we investigated the mRNA and protein expression of nine tumour antigens in
human glioblastoma multiforme with a view to their possible use in dendritic cell-based …

Significant work from many laboratories over the last decade in the study of cancer
immunology has resulted in the development of the cancer immunoediting hypothesis. This …